A real-world study of effectiveness of intravitreal bevacizumab and ranibizumab injection for treating retinal diseases in Thailand
Authors:
- Suthasinee KumluangSKSuthasinee Kumluang
- Lily IngsrisawangLILily Ingsrisawang
- Sermsiri SangroongruangsriSSSermsiri Sangroongruangsri
- Usa ChaikledkaewUCUsa Chaikledkaew
- Tanapat RatanapakornTRTanapat Ratanapakorn
- Paisan RuamviboonsukPRPaisan Ruamviboonsuk
- Wongsiri TaweebanjongsinWTWongsiri Taweebanjongsin
- Janejit ChoovuthayakornJCJanejit Choovuthayakorn
- Somanus ThoongsuwanSTSomanus Thoongsuwan
- Prut HanutsahaPHPrut Hanutsaha
- Kittisak KulvichitKKKittisak Kulvichit
- Thitiporn RatanapojnardTRThitiporn Ratanapojnard
Open Access
- 29 March 2019
- journal article
- research article
- Published by Springer Nature in BMC Ophthalmology
- Vol. 19 (1) , 1-14
Abstract
To evaluate the effectiveness of intravitreal bevacizumab (IVB) and intravitreal ranibizumab (IVR) in actual practice for treating patients with retinal diseases in Thailand. A prospective, multi-centre, observational study was conducted among eight hospitals in their ophthalmology outpatient departments. Participants consisted of patients who had previously not received any IVB or IVR treatment between 2013 and 2014. The primary outcome measurement was the change in best-corrected visual acuity (BCVA) at the end of the follow-up period compared to baseline. There were 1629 treatment-naïve patients for the pro re nata (PRN) treatment pattern and 226 treatment-naive patients for the three-injections (3Inj) treatment pattern. BCVA improvements were found in 35% of the PRN group and 47% of the 3Inj group; however, it was not clinically meaningful between the IVB and IVR groups (P-value = 0.568 for PRN, P-value = 0.103 for 3Inj). A multivariable logistic regression (using the propensity score) showed that positive factors associated with vision improvement for the PRN pattern were the number of drug injections, having retinal vein occlusion, and under 60 years of age, while good BCVA at baseline was a negative predictive factor. For the 3Inj pattern, under 60 years of age and baseline BCVA were statistically significant predictors. Nonetheless, diabetes mellitus (DM) without other comorbidities was a statistically significant predictor of low response to vision improvement compared to DM with other comorbidities. This study was the first observational, prospective study to evaluate the real-life effectiveness of IVB and IVR in Thailand. The majority of participants who used IVB or IVR showed improvements in BCVA after treatment. Further evaluation such as long-term follow-ups and subsequent comparison of effectiveness between IVB and IVR should be investigated due to the limited sample of IVR patients. Thai Clinical Trial Registry TCTR20141002001 . Registered 02 October 2014 (retrospectively registered).Keywords
Funding Information
- Health Systems Research Institute (HSRI. 59-005)
- Thailand Research Fund (RTA 5980011)
- the Royal Golden Jubilee Ph.D. Program (PHD/0180/2554)
- the Royal Golden Jubilee Ph.D. Program (PHD/0180/2554)
This publication has 50 references indexed in Scilit:
- Predictors of Visual Response to Intravitreal Bevacizumab for Treatment of Neovascular Age-Related Macular DegenerationJournal of Ophthalmology, 2013
- The use of comparative effectiveness research to inform policy decisions on the inclusion of bevacizumab for the treatment of macular diseases in Thailand's pharmaceutical benefit packageClinicoEconomics and Outcomes Research, 2012
- Fixed Monthly versus Less Frequent Ranibizumab Dosing and Predictors of Visual Response in Exudative Age-Related Macular DegenerationJournal of Ophthalmology, 2012
- A Safety Review and Meta-Analyses of Bevacizumab and Ranibizumab: Off-Label versus GoldstandardPLOS ONE, 2012
- Global Prevalence and Major Risk Factors of Diabetic RetinopathyDiabetes Care, 2012
- An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational StudiesMultivariate Behavioral Research, 2011
- Ranibizumab and Bevacizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2011
- The Prevalence of Retinal Vein Occlusion: Pooled Data from Population Studies from the United States, Europe, Asia, and AustraliaOphthalmology, 2010
- Intravitreal bevacizumab (avastin) for subfoveal neovascular age-related macular degenerationInternational Ophthalmology, 2008
- Ranibizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006